BRAF and melanoma: This finding has been observed in human PTC samples17 as well as in melanoma, atypical nevi, and common nevi.18 Zuo et al showed in 42 human papillary thyroid cancer samples that only 7.1% of PTCs with BRAF mutation had activated MAPK (dpERK)/ERK.